Revenue ($USm) 5739.4, down 16.9pc from year-earlier 4910.6
Pre-tax profit ($USm) 2250.9 v 1561.3
Net profit ($USm) 1810.0 v 1248.0
Interim dividend (US¢) 104.0 v 95.0, payable April 1
Blood products giant CSL notched up its fastest profit and revenue growth in recent years despite a uniquely challenging first half, after its flu business delivered an “exceptionally strong” performance.
Net profit surged a massive 45 per cent to $US1.8 billion ($2.32 billion) in the six months to December 31, while revenue leapt 16.9 per cent to $US5.7 billion. Usually, low double-digit revenue growth is considered a strong result.
Loading...
Yolanda Redrup is the editor of the AFR Rich List. She previously reported on technology, healthcare and Street Talk. Connect with Yolanda on Twitter. Email Yolanda at yolanda.redrup@afr.com
